Primary amyloidosis
AstraZeneca Amyloidosis Drug Fails Phase 3 Trials but Shows Potential in Subgroup
AstraZeneca; amyloidosis; anselamimab; Phase 3 trial; clinical trial failure; prespecified subgroup; rare diseases; Alexion; AL amyloidosis; drug development
Prothena Halts Drug and Plans Major Layoffs After Second Rare Disease Trial Failure
Prothena; birtamimab; AL amyloidosis; Phase III trial; drug failure; layoffs; biotech; spending cuts; business options